On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could ...
JMP Securities analyst Jason Butler reiterated a Hold rating on Athira Pharma (ATHA – Research Report) today. The company’s shares closed yesterday at $0.75. According to TipRanks, Butler is an ...
On Friday, Athira Pharma Inc (ATHA) stock saw a modest uptick, ending the day at $0.61 which represents a slight increase of $0.18 or 41.86% from the prior close of $0.43. The stock opened at $0.59 ...
Hosted on MSN3d
3 Penny Stocks to Watch Now, 11/5/24Vast Renewables, Theriva Biologics, and Athira Pharma are the 3 Penny Stocks to watch on November 5, 2024, based on TipRanks’ ...
The failure announced late Tuesday of an experimental Alzheimer’s-disease therapy marks yet another disappointment in the ...
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
As the U.S. stock market navigates a period of uncertainty with investors closely watching the presidential election and upcoming Federal Reserve interest rate decisions, opportunities continue to ...
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ...
Sept. 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback